EGFR and non-small cell lung carcinoma: Furthermore, MWA, as local consolidative therapy (performed for primary tumors and oligometastatic lesions before disease progression) after first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) treatment, led to better disease control and survival than TKIs monotherapy in EGFR-mutant advanced NSCLC patients with extracranial oligometastases (89).